Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Tariqa Ackbarali, PhD¹, Cindy Lovelace², Jonathan Strosberg, MD³, Al B. Benson III, MD, FACP, FASCO⁴ ¹PlatformQ Health, LLC, Needham, MA; ²Healing NET Foundation, Nashville, TN; ³Moffitt Cancer Center, Tampa, FL; ⁴Northwestern University, Chicago, IL

This activity is supported by educational grants from AAA (Advanced Accelerator Applications) and Ipsen.













INTRODUCTION

Targeted therapies for somatostatin receptor-positive NETs have seen significant developments in recent years. Approved and investigational somatostatin analogs for **GEP-NETs** are changing the treatment landscape for these cancers allowing for better management of



difficult-to-treat heterogeneous tumors. To improve competence in applying these advances and to consider patient perspectives in treatment selection, an educational initiative was designed in collaboration with the Healing NET Foundation.

METHODOLOGY

Educational Gaps and Program Details



Significant advancements in targeted therapies for somatostatin receptor-positive NETs

A 1-hour CME activity was


through October 2022 at

OMedLive.com.

broadcast live-online in October

Institute for Medicine (PIM)

2021 and remains on-demand




SSA for GEP-NETs are allowing for better management of difficult-to-treat tumors



designed to improve competence in applying these advances and considering patient perspectives in treatment selection


Focused on real-world and quality-of-life data, and consensus based on interviews of real guidelines related to somatostatin analogs (SSA) and peptide receptor radiotherapies (PRRT).

Module 1





Collaboration & Advocacy: Healing NET Foundation **Education:** PlatformQ Health and Postgraduate used for statistical analysis.




Highlighted patient perspectives patients with SSA and PRRT experience. This was distributed via social media through the Healing NET Foundation.



Questions asked pre-, immediate post-, and 2-months post-activity. Chi Square tests were

METHODOLOGY

Faculty




B. Benson III, MD, FACP, FASCO Professor of Medicine **Associate Director for Cooperative Groups** Robert H. Lurie Comprehensive **Cancer Center Northwestern University**


Jonathan Strosberg, MD Head, Neuroendocrine Section Chair, GI Research Program **Moffitt Cancer Center and Research Institute** Tampa, Fl


Learner Demographics



MD/NP/PA








*Target Audience: medical oncologists, endocrinologists, radiation oncologists, nuclear-medicine physicians and technologists, surgical oncologists, interventional radiologists, internists, nurses, nurse practitioners, and physician assistants.

Learner Engagement














RESULTS

Impact on Clinical Practice



Greater use of 177 Lu-DOTATATE

Better ability to diagnose and manage NET

I plan to change my practice with increased discussions and shared decision-making with patients about choices, safety, and efficacy

write-in examples

were shared

Increased understanding of

the scope of emerging

therapy for this group of

patients

Impact on Patient Experiences/Outcomes



Confidence in managing NET

> Request to add octreotide LAR on hospital formulary


Increased confidence in treatment decision-making

Patient compliance and


following of cases increased

Provider Insights

Top 3 Challenges Faced Managing a Patient With a NET



Adherence to treatment schedules




Affording therapy




Patient understanding of treatment options


Changes in Knowledge/Competence n = 397 pre-test; n = 268 post-test; *P < 0.05




Clinical application of PRRTs based on the **NETTER-1** trial results



Selection of first-line treatment for somatostatin receptor-positive NETs based on the **CLARINET** study



Selection of second-line therapy preferences for a limited treatment course and low toxicity



Prophylactic management of patients on PRRT

CONCLUSION

Assessments revealed the positive impact of live-online education on clinical practice when sharing patient perspectives in the context of clinical updates. Open-ended responses to behavioral impact questions illustrated clear improvements in clinician-reported patient experiences and outcomes, clinical practice management, and knowledge of SSA and PRRT for patients with GEP-NETs. Author contact: tackbarali@platformq.com